Alan Winston
Alan Winston
Unknown affiliation
Verified email at
Cited by
Cited by
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
International HIV Controllers Study
Science 330 (6010), 1551-1557, 2010
British HIV Association guidelines for the treatment of HIV‐1‐positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow …
Writing Group, I Williams, D Churchill, J Anderson, M Boffito, M Bower, ...
HIV medicine 15, 1-6, 2014
Controversies in HIV-associated neurocognitive disorders
S Nightingale, A Winston, S Letendre, BD Michael, JC McArthur, S Khoo, ...
The Lancet Neurology 13 (11), 1139-1151, 2014
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ...
The lancet HIV 8 (8), e474-e485, 2021
Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program
Mind Exchange Working Group, A Antinori, G Arendt, I Grant, S Letendre, ...
Clinical Infectious Diseases 56 (7), 1004-1017, 2013
Increased brain-predicted aging in treated HIV disease
JH Cole, J Underwood, MWA Caan, D De Francesco, RA Van Zoest, ...
Neurology 88 (14), 1349-1357, 2017
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial
NI Paton, RL Goodall, DT Dunn, S Franzen, Y Collaco-Moraes, ...
Jama 308 (4), 353-361, 2012
Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART
LJ Garvey, N Pavese, M Politis, A Ramlackhansingh, DJ Brooks, ...
Aids 28 (1), 67-72, 2014
Neuroinflammation in treated HIV-positive individuals: a TSPO PET study
JH Vera, Q Guo, JH Cole, A Boasso, L Greathead, P Kelleher, EA Rabiner, ...
Neurology 86 (15), 1425-1432, 2016
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0
L Ryom, A Cotter, R De Miguel, C Béguelin, D Podlekareva, JR Arribas, ...
HIV medicine 21 (10), 617-624, 2020
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication
W Stöhr, D Back, D Dunn, C Sabin, A Winston, R Gilson, D Pillay, T Hill, ...
Antiviral therapy 13 (5), 675-685, 2008
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
EC Caniglia, LE Cain, A Justice, J Tate, R Logan, C Sabin, A Winston, ...
Neurology 83 (2), 134-141, 2014
Transmission of monkeypox virus through sexual contact–A novel route of infection
J Heskin, A Belfield, C Milne, N Brown, Y Walters, C Scott, M Bracchi, ...
Journal of Infection 85 (3), 334-363, 2022
Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?
J Underwood, KR Robertson, A Winston
Aids 29 (3), 253-261, 2015
Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure
S Jose, L Hamzah, LJ Campbell, T Hill, M Fisher, C Leen, R Gilson, ...
The Journal of infectious diseases 210 (3), 363-373, 2014
HIV‐associated central nervous system diseases in the recent combination antiretroviral therapy era
UK Collaborative HIV Cohort (CHIC) Study Steering Committee
European journal of neurology 18 (3), 527-534, 2011
Psychiatric symptoms in patients receiving dolutegravir
A Fettiplace, C Stainsby, A Winston, N Givens, S Puccini, V Vannappagari, ...
JAIDS Journal of Acquired Immune Deficiency Syndromes 74 (4), 423-431, 2017
Do people living with HIV experience greater age advancement than their HIV-negative counterparts?
D De Francesco, FW Wit, A Bürkle, S Oehlke, NA Kootstra, A Winston, ...
Aids 33 (2), 259-268, 2019
Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy
A Winston, J Amin, PWG Mallon, D Marriott, A Carr, DA Cooper, S Emery
HIV medicine 7 (2), 105-111, 2006
Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1–infected individuals commencing …
A Winston, C Duncombe, PCK Li, JM Gill, SJ Kerr, R Puls, K Petoumenos, ...
Clinical infectious diseases 50 (6), 920-929, 2010
The system can't perform the operation now. Try again later.
Articles 1–20